We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Intermediate Capital Group Plc | ICG | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -6.00 | -0.28% | 2,148.00 | 16:35:03 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2,144.00 | 2,142.00 | 2,168.00 | 2,148.00 | 2,154.00 |
| Industry Sector |
|---|
| INDUSTRIAL TRANSPORTATION |
| Top Posts |
|---|
Posted at 02/9/2024 07:26 by mirandaj Be aware how they plan their strategy constantly.QUOTE Tax Strategy FY2023 icgplc.com ICG is a global alternative asset manager creating sustainable value by partnering with ambitious businesses. Our business involves raising capital from third party investors, investing that capital and maximising returns from investment for our investors. We manage over $70bn of AUM and our responsibilities set out within our global tax strategy are critical to deliver the appropriate tax outcomes for the Group, our international third party investors, our investing structures and our people. The Group’s tax team sit at the heart of the organisation and report directly to the Chief Financial and Operating Officer (“CFOO”) The Group has a low appetite for tax risk and the sustainability of our structuring arrangements are fundamental to managing the ongoing risk appetite of the Group and the certainty of tax outcomes for our stakeholders therein. The Tax Strategy published herein sets our approach to managing the tax affairs of ICG plc and its subsidiaries (together the “Group”) The Tax Strategy for the Group covers: - - - - - Our tax governance framework; Our commitment to timely and accurate tax compliance, including tax payments; Our approach to tax planning; Our ongoing controls to limit tax risk, and manage any residual risk arising; and Our commitment to build positive relationships with tax authorities and related government bodies. The publication of this Tax Strategy is in compliance with paragraph 16(2) of Schedule 19 to the Finance Act 2016 for the financial year ending 31 March 2023. |
Posted at 05/6/2024 15:54 by pvb Funding development in today’s market3 June 2024 Development viability has changed, but that may be good news for debt investors, says ICG Real Estate’s Jai Patel |
Posted at 23/5/2024 11:30 by zeppo More from this amazing company!Grey Wolf Therapeutics closes oversubscribed $50 million Series B financing expansion, led by ICG Life Sciences team, to accelerate and expand first-of-its-kind antigen modulation technology Brings total Series B funds raised to nearly $100 million Proceeds to support broadening scope of ongoing clinical trial of GRWD5769; first clinical data to be reported at ASCO 2024 Company to expand R&D efforts to develop disease-modifying therapies for autoimmune disorders Grey Wolf Therapeutics, a clinical-stage biotechnology company leveraging first-of-its-kind antigen modulation therapies to address the source of immune dysfunction in oncology and autoimmunity, today announced the closing of an oversubscribed $50 million Series B financing expansion, bringing the total amount of Series B funds raised to $99 million. The Series B expansion round was led by ICG’s Life Sciences team and included further investment from existing investors Pfizer Ventures, Andera Partners, Canaan, Earlybird Venture Capital, Oxford Science Enterprises and British Patient Capital. Proceeds from the round will be leveraged to broaden the scope of the company’s ongoing Phase 1/2 clinical trial of its lead immuno-oncology candidate, GRWD5769, in a range of solid tumour types. The funding also enables the company to expand research and development (R&D) for its versatile antigen modulation approach into treatments for autoimmune disease indications. Tracy Weightman, Associate Director at ICG, said: "Grey Wolf is an exciting growth stage UK biotechnology company with a novel and differentiated approach that has the potential to transform the lives of millions of patients globally. This investment demonstrates our commitment to building leading biotechnology companies and enabling them to compete on a global stage. We are pleased to support Grey Wolf through the next stage of its growth journey, enabling the company to advance its clinical development strategy and expand into new therapeutic areas." |
Posted at 10/11/2009 14:17 by lbo Sterling weakness remains an issue for ICG |
Posted at 24/6/2009 10:44 by lbo AIB SHARES came under pressure yesterday due to investor fears over the bank's exposure to troubled property developer Liam Carroll. The stock finished down 5 per cent at 1.65.It emerged on Monday that Mr Carroll is being personally sued for 60 million by Irish Nationwide Building Society. AIB is understood to have one of the largest exposures arising from his developments. Indeed, brokers noted that any stocks with which Mr Carroll is connected suffered steep falls yesterday. For example, ferry operator Irish Continental Group (in which he has a 29.2 per cent stake) lost almost 10 per cent or 1 to close at 9.50, while Greencore (of which he owns 29.9 per cent) fell by just under 7 per cent to 1.22 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
